News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Montana Tech was recently awarded a five-year, $24 million grant from the Army Research Laboratory to develop a program called “Materials Technology for Rare Earth Elements Processing.” This program, which responds to a critical national need to develop a supply chain for rare earth elements, is a multidisciplinary effort that will use Montana as a model for locating rare earth elements in primary and secondary sources.

Emory Hoelscher-Hull was recently awarded a prestigious public health grant based on her research into water quality in Montana; Pilar Santos was one of four winners of the 2022 Association of Environmental Health Academic Program student research competition, and Sarah Warnke was a runner-up in the competition. All three students were mentored with support from Montana NSF EPSCoR by Dr. Mari Eggers, an Assistant Research Professor in the Department of Microbiology and Immunology.

Montana’s Tonix Pharmaceuticals has announced the design of a new Phase 2 clinical trial of TNX-1300 for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial. TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support of the use of TNX-1300 as a treatment for cocaine intoxication. The company plans to submit the new protocol to the […]

Montana BioScience Alliance and BIO
|
July 2, 2022

Covid-19 opened the world’s eyes to the wonders of biotechnology. Unfortunately, though, coverage of the industry isn’t always the best. To provide more information about the ways bioscience is curing disease, solving climate change, and feeding and fueling the world in more sustainable ways, the Montana BioScience Alliance is joining with BIO to develop easy-to-read and easy-to-share news articles by independent journalists, editors, and content creators, as well as smart analysis by BIO experts. You can find it now on Bio.News.

Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO.

ARTICLES OF INTEREST

When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.

National Institutes of Health
|
March 26, 2024

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

BIO.News
|
January 30, 2024

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

NIH National Institute on Aging
|
January 18, 2024

Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR

National Institutes of Health SEED
|
January 18, 2024

Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.

NEWSLETTER

Newsletter
|
May 7, 2024

View the Spring 2024 Newsletter now!

Newsletter
|
February 20, 2024

View the Winter II 2024 Newsletter now!